Summary
The adamantane moiety was introduced in the tachykinin NK2 receptor-selective agonist [β-Ala8]-NKA(4–10) (H-Asp-Ser-Phe-Val-β-Ala-Leu-Met-NH2, MEN 10210) and in different positions of the NK2 receptor antagonist MEN 10376 (H-Asp-Tyr-d-Trp-Val-d-Trp-d-Trp-Lys-NH2) in order to investigate how this substitution affects their biological activity at tachykinin NK1, NK2 and NK3 receptors. 1-Adamantaneacetic acid (1-Ada-CH2COOH) was directly conjugated in the solid phase as the preformed OBt active ester to the N-terminal position of MEN 10210, obtaining MEN 10586 (1-Ada-CH2CO-Asp-Ser-Phe-Val-β-Ala-Leu-Met-NH2). The Pfp ester of adamantaneacetic acid (1) was prepared and used for the acylation of the N-terminal position of MEN 10376, yielding MEN 10606 (1-Ada-CH2CO-Asp-Tyr-d-Trp-Val-d-Trp-d-Trp-Lys-NH2). Compound 1 was then used to obtain the building block Fmoc-Lys(1-Ada-CH2CO)-OH as a modified amino acid for the synthesis of MEN 10818 [H-Asp-Tyr-d-Trp-Val-d-Trp-d-Trp-Lys(1-Ada-CH2CO)-NH2]. In order to investigate the biological activity of the peptide bearing the adamantane group together with the free N-terminal amino function, we synthesised MEN 10676 [H-Asp(O-2-Ada)-Tyr-d-Trp-Val-d-Trp-d-Trp-Lys-NH2] using Fmoc-Asp(O-2-Ada)-OH, in which 2-adamantanole was the protecting group of the aspartate β-COOH moiety during the peptide synthesis and survived the final peptide cleavage and deprotection carried out under controlled conditions. MEN 10586 showed an agonist activity comparable to that of the parent compound MEN 10210 at NK1 and NK2 receptors of guinea pig ileum, rabbit isolated pulmonary artery and hamster isolated trachea preparations, while it showed a 25-fold higher agonist activity at NK3 receptors of rat isolated portal vein. The three modified antagonist analogs displayed similar or reduced affinity at NK1, NK2 and NK3 receptors as compared to MEN 10376. The drop was particularly evident (>2 log units) at the NK2 receptors of the rabbit isolated pulmonay artery.
Similar content being viewed by others
References
Buck, S.H. (Ed.) The Tachykinin Receptors, Humana Press Inc., Totowa, NJ, 1995.
Maggi, C.A., Patacchini, R., Rovero, P. and Giachetti, A., J. Auton. Pharmacol., 13 (1993) 23.
Rovero, P., Pestellini, V., Rhaleb, N.E., Dion, S., Rouissi, N., Tousignant, C., Telemaque, S., Drapeau, G. and Regoli, D., Neuropeptides, 13 (1989) 263.
Rovero, P., Pestellini, V., Maggi, C.A., Patacchini, R., Regoli, D. and Giachetti, A., Eur. J. Pharmacol., 175 (1990) 113.
Romano, R., Dufresne, M., Prost, M.C., Bali, J.P., Bayerl, T.M. and Moroder, L., Biochim. Biophys. Acta, 1145 (1993) 235.
Moroder, L., Romano, R., Guba, W., Mierke, D.F., Kessler, H., Delporte, C., Winand, J. and Christophe, J., Biochemistry, 32 (1993) 13551.
Schwyzer, R., EMBO J., 6 (1987) 2255.
Lammek, B., Wang, Y.X., Gavras, I. and Gavras, H., J. Pharm. Pharmacol., 43 (1991) 887.
Michelot, R., Mayer, M., Magneney, S., Pham Van Chuong, P., Schmitt, P. and Potier, P., Eur. J. Med. Chem., 23 (1988) 243.
McElroy, A.B., Clegg, S.P., Deal, M.J., Ewan, G.B., Hagan, R.M., Ireland, S.J., Jordan, C.C., Porter, B., Ross, B.C., Ward, P. and Whittington, A.R., J. Med. Chem., 35 (1992) 2582.
Perrin, D.D. and Armarego, L.F., In Wheaton, A. (Ed.) Purification of Laboratory Chemicals, Pergamon Press, Oxford, 1988, pp. 145, 157 and 164.
Sheppard, R.C. and Williams, B.J., J. Chem. Soc., Chem. Commun., (1982) 587.
Maggi, C.A., Patacchini, R., Giuliani, S., Rovero, P., Dion, S., Regoli, D., Giachetti, A. and Meli, A., Br. J. Pharmacol., 100 (1990) 588.
Mastrangelo, D., Mathison, R., Huggel, H.J., Dion, S., Juste D'Orleans, P., Rhaleb, N.E., Drapeau, G., Rovero, P. and Regoli, D., Eur. J. Pharmacol., 134 (1986) 321.
Dion, S., Juste D'Orleans, P., Drapeau, G., Rhaleb, N.E., Rouissi, N., Tousignant, C. and Regoli, D., Life Sci., 41 (1987) 2269.
Arunlakshana, O. and Schild, H.O., Br. J. Pharmacol. Chemother., 14 (1959) 48.
Kisfaludy, L. and Schon, I., Synthesis, (1983) 325.
Okada, Y., Iguchi, S. and Kawasaki, K., J. Chem. Soc., Chem. Commun., (1987) 1532.
Okada, Y. and Iguchi, S., J. Chem. Soc., Perkin Trans. I, (1988) 2129.
Patacchini, R., Astolfi, M., Quartara, L., Rovero, P., Giachetti, A. and Maggi, C.A., Br. J. Pharmacol., 104 (1991) 91.
Maggi, C.A., Giuliani, S., Ballati, L., Lecci, A., Manzini, S., Patacchini, R., Renzetti, A.R., Rovero, P., Quartara, L. and Giachetti, A., J. Pharmacol. Exp. Ther., 257 (1991) 1172.
Drapeau, G., Rouissi, N., Nantel, F., Rhaleb, N.E., Tousignant, C. and Regoli, D., Regul. Pept., 31 (1990) 125.
Rovero, P., Quartara, L., Astolfi, M., Patacchini, R., Giachetti, A. and Maggi, C.A., Peptides, 13 (1992) 207.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Pinzani, D., Papini, A.M., Chelli, M. et al. Synthesis and biological activity of tachykinin analogs containing the adamantane moiety. Lett Pept Sci 2, 307–313 (1996). https://doi.org/10.1007/BF00142244
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00142244